ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 136 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $44,588 | -74.5% | 28,043 | 0.0% | 0.00% | – |
| Q4 2022 | $174,708 | -1.7% | 28,043 | +5.7% | 0.00% | – |
| Q3 2022 | $177,744 | +14.7% | 26,529 | +8.8% | 0.00% | – |
| Q2 2022 | $155,000 | -29.5% | 24,387 | -48.6% | 0.00% | – |
| Q1 2022 | $220,000 | +71.9% | 47,435 | +347.8% | 0.00% | – |
| Q3 2021 | $128,000 | -42.9% | 10,593 | 0.0% | 0.00% | – |
| Q2 2021 | $224,000 | -32.1% | 10,593 | -10.1% | 0.00% | -100.0% |
| Q1 2021 | $330,000 | +13.8% | 11,780 | +5.6% | 0.00% | 0.0% |
| Q4 2020 | $290,000 | -12.4% | 11,156 | +25.2% | 0.00% | 0.0% |
| Q3 2020 | $331,000 | -27.6% | 8,909 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $457,000 | +14.8% | 8,909 | -29.3% | 0.00% | 0.0% |
| Q1 2020 | $398,000 | -45.6% | 12,609 | +2.8% | 0.00% | -50.0% |
| Q4 2019 | $731,000 | +104.8% | 12,262 | +26.1% | 0.00% | +100.0% |
| Q3 2019 | $357,000 | -21.0% | 9,725 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $452,000 | +19.3% | 9,725 | +2.9% | 0.00% | 0.0% |
| Q1 2019 | $379,000 | -12.9% | 9,451 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $435,000 | -91.3% | 9,451 | -91.6% | 0.00% | -90.0% |
| Q3 2018 | $5,009,000 | -68.1% | 112,888 | -71.8% | 0.01% | -69.7% |
| Q2 2018 | $15,709,000 | -31.5% | 400,813 | +26.3% | 0.03% | -32.7% |
| Q1 2018 | $22,948,000 | +4444.2% | 317,262 | +4034.8% | 0.05% | +4800.0% |
| Q4 2017 | $505,000 | +31.2% | 7,673 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $385,000 | +16.3% | 7,673 | +7.3% | 0.00% | 0.0% |
| Q2 2017 | $331,000 | +47.8% | 7,148 | +12.7% | 0.00% | 0.0% |
| Q1 2017 | $224,000 | -97.7% | 6,342 | -99.1% | 0.00% | -94.4% |
| Q3 2016 | $9,555,000 | +3.8% | 689,910 | -25.9% | 0.02% | -21.7% |
| Q2 2016 | $9,202,000 | -13.9% | 931,360 | +47.3% | 0.02% | -14.8% |
| Q1 2016 | $10,693,000 | +7.3% | 632,392 | +41.2% | 0.03% | +12.5% |
| Q4 2015 | $9,969,000 | +51.4% | 447,842 | +60.5% | 0.02% | +41.2% |
| Q3 2015 | $6,584,000 | -57.1% | 279,067 | +48.8% | 0.02% | -51.4% |
| Q2 2015 | $15,337,000 | +232.2% | 187,592 | +276.2% | 0.04% | +250.0% |
| Q1 2015 | $4,617,000 | – | 49,865 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |